Biosergen AS
Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
Biosergen AS (BIOSGN) - Net Assets
Latest net assets as of December 2025: Skr8.12 Million SEK
Based on the latest financial reports, Biosergen AS (BIOSGN) has net assets worth Skr8.12 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr21.16 Million) and total liabilities (Skr13.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr8.12 Million |
| % of Total Assets | 38.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | -59.88% |
| 10-Year Change | N/A |
| Growth Volatility | 986.47 |
Biosergen AS - Net Assets Trend (2019–2025)
This chart illustrates how Biosergen AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biosergen AS (2019–2025)
The table below shows the annual net assets of Biosergen AS from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.12 Million | -83.48% |
| 2024-12-31 | Skr49.14 Million | +2222.35% |
| 2023-12-31 | Skr2.12 Million | -90.72% |
| 2022-12-31 | Skr22.79 Million | +12.66% |
| 2021-12-31 | Skr20.23 Million | +285.22% |
| 2020-12-31 | Skr-10.92 Million | -132.84% |
| 2019-12-31 | Skr-4.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biosergen AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3399491700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr8.12 Million | 100.00% |
| Total Equity | Skr8.12 Million | 100.00% |
Biosergen AS Competitors by Market Cap
The table below lists competitors of Biosergen AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zenith Exports Limited
NSE:ZENITHEXPO
|
$2.76 Million |
|
Charn Issara Development Public Company Limited
BK:CI
|
$2.76 Million |
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
$2.76 Million |
|
CIENA - Dusseldorf Stock Exchang
DU:CIE1
|
$2.76 Million |
|
Computer Direct
TA:CMDR
|
$2.76 Million |
|
City Office
NYSE:CIO
|
$2.76 Million |
|
CREDICORP (D8V.SG)
STU:D8V
|
$2.76 Million |
|
NOVA MEASURING INTR
BE:NMR
|
$2.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biosergen AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,208,000 to 8,117,000, a change of -40,091,000 (-83.2%).
- Net loss of 40,817,000 reduced equity.
- Other factors increased equity by 726,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-40.82 Million | -502.86% |
| Other Changes | Skr726.00K | +8.94% |
| Total Change | Skr- | -83.16% |
Book Value vs Market Value Analysis
This analysis compares Biosergen AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 10.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | Skr-2.26 | Skr36.40 | x |
| 2020-12-31 | Skr-42.02 | Skr36.40 | x |
| 2021-12-31 | Skr37.83 | Skr36.40 | x |
| 2022-12-31 | Skr43.20 | Skr36.40 | x |
| 2023-12-31 | Skr4.71 | Skr36.40 | x |
| 2024-12-31 | Skr20.09 | Skr36.40 | x |
| 2025-12-31 | Skr3.46 | Skr36.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biosergen AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -502.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.61x
- Recent ROE (-502.86%) is below the historical average (-305.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -412.48% | 0.20x | 0.00x | Skr-4.95 Million |
| 2020 | 0.00% | -162.95% | 0.92x | 0.00x | Skr-6.13 Million |
| 2021 | -170.80% | -403.10% | 0.29x | 1.46x | Skr-36.58 Million |
| 2022 | -149.37% | 0.00% | 0.00x | 1.48x | Skr-36.33 Million |
| 2023 | -1277.74% | 0.00% | 0.00x | 3.40x | Skr-27.25 Million |
| 2024 | -39.82% | 0.00% | 0.00x | 1.10x | Skr-24.02 Million |
| 2025 | -502.86% | 0.00% | 0.00x | 2.61x | Skr-41.63 Million |
Industry Comparison
This section compares Biosergen AS's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $68,244,097
- Average return on equity (ROE) among peers: -147.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biosergen AS (BIOSGN) | Skr8.12 Million | 0.00% | 1.61x | $2.76 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |